NewAmsterdam Pharma Company NAMS Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

SoundHound AI, Inc.SOUN

$0-100%

STU

StubHub Holdings, Inc.STUB

$2.06M—

Immunovant, Inc.IMVT

$126K-60.5%

NTS

Netskope, Inc. Class A Common StockNTSK

$0-100%

ArriVent BioPharma, Inc.AVBP

$17K—

McGraw Hill, Inc.MH

$0—

Other financials

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

See full

Market cap$3.67B+63.7%

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's payments of stock issuance costs?: NewAmsterdam Pharma Company (NAMS) reported payments of stock issuance costs of $1.59M in Q1 2025.